Comparative Pharmacology
Head-to-head clinical analysis: ADHANSIA XR versus AMPHETAMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADHANSIA XR versus AMPHETAMINE SULFATE.
ADHANSIA XR vs AMPHETAMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adhansia XR is a central nervous system (CNS) stimulant. The mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully known, but it is thought to involve blockade of norepinephrine and dopamine reuptake into presynaptic neurons, increasing their levels in the synaptic cleft. This enhances attention and reduces impulsivity.
Increases presynaptic release of dopamine and norepinephrine, blocks reuptake, and inhibits monoamine oxidase, resulting in CNS stimulation.
Methylphenidate hydrochloride extended-release: Oral, 18-72 mg once daily in the morning.
5–60 mg/day orally in 1–3 divided doses, initial 5 mg once or twice daily, increase by 5 mg weekly.
None Documented
None Documented
Mean terminal elimination half-life is 7.5 hours (range 5-10 hours) following oral administration, allowing twice-daily dosing.
Terminal elimination half-life: 10-13 hours in adults with acidic urine; prolonged to 16-34 hours with alkaline urine. In children, half-life is typically shorter (6-8 hours).
Primarily renal (78% as unchanged drug), with 10% biliary/fecal elimination.
Renal excretion of unchanged amphetamine (approximately 30-40%) and its metabolites; urinary pH-dependent: acidic urine enhances elimination (up to 70% unchanged), alkaline urine reduces it. Minor biliary/fecal elimination (<10%).
Category C
Category D/X
CNS Stimulant
CNS Stimulant